Signed an Exclusive Distributorship Agreement with Accelerated Biosciences, US Cell Provider

Summit Pharmaceuticals International Corporation (Headquarters: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama, hereinafter “SPI”) has signed an exclusive distributorship agreement with Accelerated Biosciences (Headquarters: Philadelphia, USA; CEO: Yuta Lee, hereinafter “AB”), a US-based company to expand and promote the use of the human trophoblast stem cell (human Trophoblast Stem Cell, hereinafter “hTSC”) and induced pluripotent stem cell reprogrammed from the hTSC (Trophoblast induced Pluripotent Stem Cell, hereinafter “TiPSC”) for advanced therapy and medicinal products (“ATMP”).

 

Recently, the practical application of regenerative medicines and diversification of modalities have led to an increase in the development of biological products in the pharmaceutical industry in Japan. SPI has been expanding services and building frameworks to meet these diversified needs.

 

AB, established in 2013, is a biotech company that leverages the groundbreaking potential of hTSCs, manufacturing and developing hTSCs as new cell materials for use in the cell therapy and for the secretions such as exosomes. hTSCs are cells collected at the earliest pre-implantation stage and TiPSC, iPSC reprogrammed from hTSC, would offer better characteristics than those from adult somatic cells. As ideal starting materials for ATMP therapeutic development and regenerative medicine, hTSCs possess various properties, including genetic stability, natural immune privilege, and high proliferative capacity.

 

Since June 2023, SPI formed the New Modalities Support Group, strengthening the support for the pharmaceutical development specifically in the antibody, exosome and nucleic acid therapeutics. In particular, for upstream cell materials, we offer a diverse lineup ranging from research-use cells provided by ATCC (American Type Culture Collection, The world’s largest biorepository) to those suitable for clinical and commercial use. Through this partnership with AB, SPI will further expand and strengthen the existing services and will continue to work with AB to promote pharmaceutical research and development in Japanese market.

 

[Contact]
Summit Pharmaceuticals International Corporation
Discovery & Alliance Coordination Dept. New Modalities Support Group
Tel: +81-3-5220-1560
Email: alliance@summitpharma.co.jp

 

Accelerated Biosciences Corp.
E-mail: info@acceleratedbio.com
HP: https://www.acceleratedbio.com/